These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 31021531)

  • 1. Budget impact of intravenous ferric carboxymaltose in patients with chronic heart failure and iron deficiency in France.
    Bourguignon S; Faller M; Champs FO; Moutier H; Levesque K; Caranhac G; Cohen-Solal A
    ESC Heart Fail; 2019 Jun; 6(3):559-569. PubMed ID: 31021531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness analysis of ferric carboxymaltose in iron-deficient patients with chronic heart failure in Sweden.
    Hofmarcher T; Borg S
    J Med Econ; 2015; 18(7):492-501. PubMed ID: 25766863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ferric carboxymaltose for patients with heart failure and iron deficiency in Italy: cost-effectiveness and budget impact.
    Rognoni C; Gerzeli S
    J Comp Eff Res; 2019 Oct; 8(13):1099-1110. PubMed ID: 31580153
    [No Abstract]   [Full Text] [Related]  

  • 4. Evaluation of cost savings with ferric carboxymaltose in anemia treatment through its impact on erythropoiesis-stimulating agents and blood transfusion: French healthcare payer perspective.
    Luporsi E; Mahi L; Morre C; Wernli J; de Pouvourville G; Bugat R
    J Med Econ; 2012; 15(2):225-32. PubMed ID: 22077267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Cost-effectiveness Analysis of Ferric Carboxymaltose in Patients With Iron Deficiency and Chronic Heart Failure in Spain.
    Comín-Colet J; Rubio-Rodríguez D; Rubio-Terrés C; Enjuanes-Grau C; Gutzwiller FS; Anker SD; Ponikowski P
    Rev Esp Cardiol (Engl Ed); 2015 Oct; 68(10):846-51. PubMed ID: 25649970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost effectiveness of implementing ESC guidelines for treatment of iron deficiency in heart failure in the Nordic countries.
    Hofmarcher T; Cabrales Alin D; Linde C
    Scand Cardiovasc J; 2018 Dec; 52(6):348-355. PubMed ID: 30457358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial.
    Ponikowski P; Kirwan BA; Anker SD; McDonagh T; Dorobantu M; Drozdz J; Fabien V; Filippatos G; Göhring UM; Keren A; Khintibidze I; Kragten H; Martinez FA; Metra M; Milicic D; Nicolau JC; Ohlsson M; Parkhomenko A; Pascual-Figal DA; Ruschitzka F; Sim D; Skouri H; van der Meer P; Lewis BS; Comin-Colet J; von Haehling S; Cohen-Solal A; Danchin N; Doehner W; Dargie HJ; Motro M; Butler J; Friede T; Jensen KH; Pocock S; Jankowska EA;
    Lancet; 2020 Dec; 396(10266):1895-1904. PubMed ID: 33197395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Budget impact of parenteral iron treatment of iron deficiency: methodological issues raised by using real-life data.
    Brock E; Braunhofer P; Troxler J; Schneider H
    Eur J Health Econ; 2014 Dec; 15(9):907-16. PubMed ID: 24081613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health economic assessment of ferric carboxymaltose in patients with iron deficiency and chronic heart failure based on the FAIR-HF trial: an analysis for the UK.
    Gutzwiller FS; Schwenkglenks M; Blank PR; Braunhofer PG; Mori C; Szucs TD; Ponikowski P; Anker SD
    Eur J Heart Fail; 2012 Jul; 14(7):782-90. PubMed ID: 22689292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of a multifaceted intervention to promote the use of intravenous iron sucrose complex instead of ferric carboxymaltose in patients admitted for more than 24 h.
    Touchard J; Perrin G; Berdot S; Pouchot J; Loustalot MC; Sabatier B
    Eur J Clin Pharmacol; 2021 Feb; 77(2):189-195. PubMed ID: 32926203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ferric carboxymaltose: a review of its use in iron deficiency.
    Keating GM
    Drugs; 2015 Jan; 75(1):101-27. PubMed ID: 25428711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ferric carboxymaltose in patients with heart failure and iron deficiency.
    Anker SD; Comin Colet J; Filippatos G; Willenheimer R; Dickstein K; Drexler H; Lüscher TF; Bart B; Banasiak W; Niegowska J; Kirwan BA; Mori C; von Eisenhart Rothe B; Pocock SJ; Poole-Wilson PA; Ponikowski P;
    N Engl J Med; 2009 Dec; 361(25):2436-48. PubMed ID: 19920054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The health care cost of intravenous iron treatment in IBD patients depends on the economic evaluation perspective.
    Bager P; Dahlerup JF
    J Crohns Colitis; 2010 Oct; 4(4):427-30. PubMed ID: 21122539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in Denmark.
    Pollock RF; Muduma G
    Adv Ther; 2018 Dec; 35(12):2128-2137. PubMed ID: 30456520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Economic impact of ferric carboxymaltose in haemodialysis patients].
    Aiello A; Berto P; Conti P; Panichi V; Rosati A
    G Ital Nefrol; 2020 Aug; 37(Suppl 75):. PubMed ID: 32749086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Budget impact of ferric carboxymaltose treatment in patients with chronic heart failure and iron deficiency in Spain.
    Delgado JF; Oliva J; González-Franco Á; Cepeda JM; García-García JÁ; González-Domínguez A; Garcia-Casanovas A; Jiménez Merino S; Comín-Colet J
    J Med Econ; 2020 Dec; 23(12):1418-1424. PubMed ID: 33073660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ferric Carboxymaltose: A Review in Iron Deficiency.
    Scott LJ
    Drugs; 2018 Mar; 78(4):479-493. PubMed ID: 29532438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and cost effectiveness of intravenous ferric carboxymaltose versus iron sucrose in adult patients with iron deficiency anaemia.
    Basha A; Ibrahim MIM; Hamad A; Chandra P; Omar NE; Abdullah MAJ; Aldapt MB; Hussein RM; Mahfouz A; Adel AA; Shwaylia HM; Ekeibed Y; AbuMousa R; Yassin MA
    PLoS One; 2021; 16(8):e0255104. PubMed ID: 34375369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rationale and design of the IRON-CRT trial: effect of intravenous ferric carboxymaltose on reverse remodelling following cardiac resynchronization therapy.
    Martens P; Dupont M; Dauw J; Somers F; Herbots L; Timmermans P; Verwerft J; Mullens W
    ESC Heart Fail; 2019 Dec; 6(6):1208-1215. PubMed ID: 31562751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Budget impact of intravenous iron therapy with ferric carboxymaltose in patients with chronic heart failure and iron deficiency in Germany.
    Theidel U; Väätäinen S; Martikainen J; Soini E; Hardt T; Doehner W
    ESC Heart Fail; 2017 Aug; 4(3):274-281. PubMed ID: 28772041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.